Deferoxamine mesylate

Deferoxamine Mesylate is a medication primarily used in the management and treatment of acute iron intoxication and chronic iron overload due to transfusion-dependent anemias. It is a chelating agent that binds free iron in the bloodstream, allowing it to be excreted by the kidneys. This reduces the toxic effects of excess iron in the body, which can damage organs such as the heart and liver. Deferoxamine Mesylate is often referred to by its brand name, Desferal.

Medical Uses

Deferoxamine Mesylate is indicated for the treatment of:

• Acute Iron Poisoning: It is used in cases of acute overdose of iron-containing products.
• Chronic Iron Overload: Patients with conditions requiring frequent blood transfusions, such as thalassemia, sickle cell disease, and myelodysplastic syndromes, are at risk of accumulating toxic levels of iron in their bodies. Deferoxamine helps in reducing this iron overload.

Mechanism of Action

Deferoxamine Mesylate acts by binding to free iron in the blood, forming a complex that is readily excreted in the urine. This process not only reduces the levels of toxic free iron but also prevents the iron from entering into further harmful reactions within the body. The drug has a high affinity for ferric iron (Fe3+) but does not bind significantly to other metals, making it specific in its action against iron overload.

Administration

Deferoxamine Mesylate is administered via subcutaneous, intramuscular, or intravenous routes. The mode of administration depends on the severity of the iron overload, the patient's overall health status, and the treatment setting.

Side Effects

While Deferoxamine Mesylate is effective in managing iron overload, it can have side effects, including:

• Yersinia infections
• Visual disturbances
• Hearing loss
• Allergic reactions

Patients are monitored closely for any adverse effects during therapy, and doses are adjusted as necessary to minimize risks.

Precautions

Before starting Deferoxamine Mesylate, patients should be screened for:

• Existing kidney disease
• Hearing impairment
• Pregnancy and breastfeeding considerations

Interactions

Deferoxamine Mesylate can interact with other medications, potentially altering their effects. It is important to inform healthcare providers of all medications being taken before starting treatment with Deferoxamine.

Pharmacokinetics

The pharmacokinetics of Deferoxamine Mesylate involve its rapid binding to free iron in the bloodstream and its excretion primarily through the kidneys. The drug's half-life and excretion can be affected by the patient's renal function.

Research

Research into Deferoxamine Mesylate has explored its potential use in other conditions associated with oxidative stress and iron-mediated damage, including certain neurodegenerative diseases. However, these uses are not currently approved and are considered experimental.

Conclusion

Deferoxamine Mesylate is a critical tool in the management of iron overload conditions. Its use must be carefully monitored to balance its benefits in reducing iron toxicity against the risks of side effects and interactions.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian